Actively Recruiting
Phase 1b Study Evaluating NXP900 Combined with Lorlatinib in Advanced ALK-Positive Non-Small Cell Lung Cancer
Led by Nuvectis Pharma, Inc. · Updated on 2026-08-25
54
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of NXP900 with lorlatinib in patients who have advanced ALK-positive non-small cell lung cancer NSCLC. This Phase 1b, multi-center, open-label study aims to explore the safety and efficacy of this drug combination in subjects who have previously been treated with lorlatinib. The study is sponsored by Nuvectis Pharma, Inc. and targets patients with unresectable, metastatic, or locally advanced ALK-positive NSCLC. Participants will receive escalating doses of NXP900 together with lorlatinib. NXP900 is an oral inhibitor of SRC family kinases, while lorlatinib is a kinase inhibitor used in metastatic NSCLC. The study focuses on dose exploration of this combination to assess treatment-related adverse events and clinical laboratory abnormalities. The dosing schedule is sequential, with doses adjusted during the study to determine tolerability and response. Throughout the study, participants will be monitored for adverse events up to 30 days post treatment. Researchers will also evaluate objective response rate, duration of response, and disease control rate for up to approximately 12 months. The study involves regular assessments to track safety and treatment effectiveness, with a total participation duration spanning from treatment initiation through follow-up over about a year.
CONDITIONS
Brief Title
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
Research Team
E
Erin Belshaw
S
Shay Shemesh
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here